BurnC REACTIVE PRONCT07855432
THE EFFECT OF CRP/LYMPHOCYTE AND NEUTROPHIL/LYMPHOCYTE RATIOS ON LENGTH OF HOSPITAL STAY AND MORTALITY IN PATIENTS ADMITTED TO THE BURN UNIT
An observational study of Burn, run by Samsun University at 1 site in Turkey (Türkiye).
Trial summary
This retrospective study aims to evaluate the prognostic value of systemic inflammatory markers, specifically the C-reactive protein-to-lymphocyte ratio (CLR) and neutrophil-to-lymphocyte ratio (NLR), in patients admitted to the burn intensive care unit. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Burn
- What is being tested?
- Routine blood samples collected for CRP, neutrophil, and lymphocyte counts during ICU admission.
- How many people
- 500 participants
- Where
- 1 siteTurkey (Türkiye)
- Study dates
- 1 Jan 2020to 30 Sep 2026
- Phase
- Observational
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: The study population consists of adult patients (aged 18 years and older) who were admitted to the Burn Intensive Care Unit (BICU) of Samsun Training and Research Hospital between January 2020 and December 2025. Patient data will be extracted retrospectively from electronic medical records. Eligible participants are those with confirmed acute burn injuries whose routine laboratory investigations (complete blood count and C-reactive protein) were performed upon admission.
Who may be able to join
- Patients with missing data
- Patients with chronic inflammatory disease (optional)
- Pediatric patients under 18 years of age
- Patients with a hospital stay of less than one day
Who cannot join
- Patients with missing data
- Patients with chronic inflammatory disease (optional)
- Pediatric patients under 18 years of age
- Patients with a hospital stay of less than one day
Trial locations and contacts
1 site in 1 country.
About this study
This retrospective study aims to evaluate the prognostic value of systemic inflammatory markers, specifically the C-reactive protein-to-lymphocyte ratio (CLR) and neutrophil-to-lymphocyte ratio (NLR), in patients admitted to the burn intensive care unit. Burn injury triggers a profound systemic inflammatory response, which significantly influences clinical outcomes. By analyzing medical records, the study investigates whether admission or dynamic changes in CLR and NLR correlate with the length of hospital stay (LOS) and in-hospital mortality. The ultimate goal is to identify cost-effective, readily available biomarkers for early risk stratification in severe burn management.
Read the detailed description
Severe burn injuries induce a complex pathophysiology characterized by extensive tissue damage, systemic inflammation, hypermetabolism, and immune dysregulation. Early assessment of disease severity and risk stratification is critical for optimizing treatment strategies and improving patient survival in burn units. Traditional scoring systems often require multiple parameters, whereas routine complete blood counts and inflammatory markers offer rapid, cost-effective alternatives.
This retrospective observational cohort study evaluates the clinical utility of the C-reactive protein-to-lymphocyte ratio (CLR) and the neutrophil-to-lymphocyte ratio (NLR) as prognostic indicators in adult patients treated in the burn intensive care unit.
Study Objectives:
Primary Objective: To evaluate the association between admission CLR and NLR values and overall in-hospital mortality among burn unit patients.
Secondary Objective: To determine the relationship between initial/longitudinal CLR and NLR dynamics and the total length of hospital stay (LOS), length of ICU stay, and complication rates (e.g., sepsis, acute kidney injury).
Methodology:
Patient data will be extracted retrospectively from hospital electronic medical records. Laboratory parameters-including complete blood count (neutrophil and lymphocyte counts) and C-reactive protein (CRP) levels measured upon admission (and at predefined intervals, if applicable)-will be recorded to calculate CLR and NLR values. Demographic data (age, sex), clinical variables (total body surface area burned [TBSA], burn depth, inhalation injury status, etiology of burn) and clinical outcomes (LOS and mortality) will be documented.
- Conditions
- Burn
- Being tested
- Routine blood samples collected for CRP, neutrophil, and lymphocyte counts during ICU admission.
- Medical subject headings
- Burns
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Routine blood samples collected for CRP, neutrophil, and lymphocyte counts during ICU admission.Other
Routinely checked complete blood count and biochemistry tests
| Study group | Role | What they receive |
|---|---|---|
| Burn Unit Patients | Adult patients (≥18 years) admitted to the burn intensive care unit whose medical records, including complete blood counts and CRP levels, are evaluated retrospectively. Receives: Other: Routine blood samples collected for CRP, neutrophil, and lymphocyte counts during ICU admission. |
What is being measured
The primary outcome is the main question the study is designed to answer.
In-Hospital Mortality
Evaluation of the association between baseline CRP/lymphocyte ratio (CLR) and neutrophil/lymphocyte ratio (NLR) values upon admission and the occurrence of all-cause in-hospital mortality.
Measured: 01.01.2020 - 31.12.2025
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted2 Oct 2026
- Study start1 Jan 2020
- Primary completion31 Dec 2025
- Study completion30 Sep 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for BurnStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Retrospective
- Enrolment
- 500 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Samsun University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Hatice Bahadır Altun, Samsun University
- Investigators
- Hatice Bahadır Altun, Principal investigator, SAMSUN UNIVERSITESI
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07855432
- Sponsor's protocol ID
- GOKAEK 2026/6/3
- Acronym
- C REACTIVE PRO
- Status last verified
- Sep 2026
- First submitted
- 28 Sep 2026
- Last updated
- 2 Oct 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: No information will be shared, in order to protect the patient's personal data.
Publications
Pao-Jen Kuo, Ching-Ya Huang, Kuan-Hao Liao, Ching-Hua Tsai, Wei-Ti Su, Shiun-Yuan Hsu, Ching-Hua Hsieh. Association of C-reactive protein-to-lymphocyte ratio and mortality outcome in patients with trauma admitted to an intensive care unit. Signa Vitae. 2026; 22(2): 96-103. doi: 10.22514/sv.2025.183